ABAC Therapeutics was founded in 2014 with the aim of discovering and developing new antibacterial agents with a new perspective focused on precision medicine. The research is focused on the discovery of antibiotics with specific activity against pathogenic bacteria, that is, they cause infections in humans. Domingo Gargallo-Viola, co-founder and CEO of the company, assures that “we try to follow the evolution that the world of oncology had been following until now”, that is, to apply precision medicine to the treatment of infectious diseases. With this, ABAC aspires to contribute great value to society, reducing the detrimental clinical and economic impact derived from the selection of multi-resistant bacteria that arise as a consequence of the indiscriminate and nonspecific use that is currently made of antibiotics.
Both he and his team embarked on an innovative as well as disruptive project, with a clear objective: to add value and improve people’s quality of life. The idea was structured around a pharmacological strategy based on a new algorithm that would allow them to discover specific antibacterials capable of effectively fighting infections caused by multi-resistant bacteria, immune to available antibiotics. “Of our body weight, around 1 kg are bacteria, which are not only not pathogenic, but are great allies of our body,” says Domingo.
Of our body weight, around 1 kg are bacteria, which are not only non-pathogenic, but are great allies of our body ”Domingo Gargallo-ViolaCofounder and CEO of ABAC Therapeutic
Therefore, the aim of ABAC is to discover antibiotics that selectively eliminate pathogenic bacteria, respecting the microbiome, which fulfills a protective function and is necessary to carry out many vital functions of our body. “With our new therapeutic approach, what is achieved is to protect the microbiome and significantly reduce the generation of resistant bacteria. With a long-term vision, we extend the useful life of the compounds and therefore their value from the commercial point of view in the future ”. Undoubtedly, a vision that sheds light on the industry and the health system, and specifically on the different actors that are part of the antibacterial drug discovery and development sector, as it adds, “It is a complex and high-risk area. , because regarding their use in the clinic they are not the most attractive compounds for the sector due to the short duration of the treatments ”.
However, the pandemic caused by Covid-19 has meant a paradigm shift not only in the health aspect, but also in the way of thinking of society and the need to have a powerful and innovative therapeutic arsenal to face the infectious diseases.
“With the pandemic, society as a whole has become aware of the need to invest and strengthen the health sector, the importance of research, and the commitment to new solutions that favor the development of disruptive projects, we cannot remember the health and hospitals only when we need them ”, says the executive director of this company. “We have realized that without health there is no development and without new therapeutic options we will not be able to face the current and future challenges posed by pathogens,” says Domingo, “and in our case we have assumed the exciting challenge of investigating and develop new antibiotics based on modern and precision medicine ”.
The vision of ABAC Therapeutics is very broad and with great aspirations, so much so that in 2021 they are exploring alliances with strategically important areas from an epidemiological point of view such as India or South Africa, establishing links with groups from the same sector to promote research and curb the devastating effect of infectious diseases, which according to the World Health Organization, pose one of the greatest threats to Global Health of the 21st century. If any positive aspect of this health crisis can be extracted, it is the awareness on the part of public administrations, private entities and, in general, society, to be more interested in what is currently happening in the field of health and give account of the importance of betting on R + D + i in this area.
This crisis has promoted familiarization with concepts that were previously only used in a scientific environment, something extremely positive due to the support that is being received from society directly and indirectly. But not only that, but this crisis has promoted that science and researchers are even on the front page of many media, and that society listens and highly respects the contribution and contribution of scientists to the challenges that directly affect the citizens.
With the pandemic, society as a whole has become aware of the need to invest and strengthen the health sector
“R + D + i should continue to be at the forefront of society,” says Domingo, “since their support for companies like ABAC to continue taking on challenges and future scientific and technological development is essential.” “Administrations and private entities have to bear the responsibility of being visionary and responding to problems such as the one we are experiencing and generating the means to effectively address others that may be looming in the future,” says this doctor in microbiology and parasitology with more than 30 years of experience in the discovery and development of anti-infective drugs. As if the figures of people who died due to bacteria resistant to antibiotics today were not dangerous, it launches a much more disturbing figure, such as the forecast of reaching around 10 million deaths from this cause in the year 2050.
Kaudal has provided the company with a means of private financing that has provided them with a new alternative to continue investigating highly innovative projects that involve a great effort in R&D, such as the one they have developed thanks to the Technological Patronage tool, a project focused on implanting precision medicine in anti-infective treatments. Kaudal is a company that is committed to R + D + i and that facilitates the processes of development of the ideas that they want to carry out. But if there is a value that he puts up on his dealings with Kaudal, it is “the motivation they have for the commitment to disruptive projects that, after all, are those that have a high impact on society and that require the accompaniment of a trusted partner that provides what you need at all times ”.
In the last three years, Kaudal has promoted more than 155 Technological Patronage projects, worth more than 200 million euros
As an agent of the R + D + i ecosystem, Kaudal continues to bet on attracting private resources to relevant projects in all sectors of activity and very specifically in sectors that have research and development in their DNA, such as the biomedical sector, and For this, it has created a program of calls launched last March, Orbita.k. The purpose of Orbita.k is to identify impact projects to promote them through Technological Patronage – a collaborative private investment instrument based on tax incentives applicable to R & D & I that channels private resources to non-refundable funds towards R&D projects. D and technological innovation.
In the last three years, Kaudal has promoted more than 155 Technological Patronage projects, worth more than 200 million euros, its aspiration is that entrepreneurs and companies can carry out their projects in an agile way, accompanied by a close partner and trustworthy, and counting on the necessary certainty to tackle your projects.
The ecosystem where good ideas gravitate ORBITA-K
Orbita-k is a private call program aimed at companies, mainly SMEs and start-ups and private R & D & i entities.
The main objective is the identification of R & D & i proposals that are promoted with private resources to contribute to the sustained growth of the research ecosystem in Spain and to the generation of economic and social impact.
If you have a new and innovative project and want to launch yourself in the R & D & I market, contact us and send us your proposal to orbita-k.es and join the orbit.